Abraham Morgentaler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abraham Morgentaler has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Abdulmaged Traish
Boston University School of Medicine
8 shared publications Abdulmaged M. Traish
Boston University School of Medicine, Boston University, Boston, Massachusetts
6 shared publicationsStephen Lazarou
Division of Urology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
4 shared publicationsT. Hugh Jones
Robert Hague Centre for Diabetes and Endocrinology, Barnsley Hospital
4 shared publicationsAbdulmaged Traish
Boston University School of Medicine, Boston, Massachusetts
3 shared publicationsAdrian S. Dobs
Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD
3 shared publications
Latest Publications
- 1 December 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (6) , 813
Editorial Comment
- 1 December 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (6) , 813
Editorial Comment
- Open Access
- 26 August 2026
- Published by Taylor & Francis in The Aging Male
- Vol. 29 (1) , 2716438
Managing testosterone deficiency in primary care: an international expert consensus
General practitioners (GPs) are often the first point of contact for men with testosterone deficiency (TD), however, TD has traditionally been considered a condition reserved for specialists [1]. V...
- 26 August 2026
- Published by Taylor & Francis in The Aging Male
- Vol. 29 (1) , 2716438
Open AccessManaging testosterone deficiency in primary care: an international expert consensus
General practitioners (GPs) are often the first point of contact for men with testosterone deficiency (TD), however, TD has traditionally been considered a condition reserved for specialists [1]. V...
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (6) , 701
Reply by Authors
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (6) , 701
Reply by Authors
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (6) , 688-701
Testosterone Does Not Drive Prostate Cancer: Presenting the New Framework of Androgen Adequacy vs Inadequacy
1) To review the evidence whether "testosterone drives prostate cancer"; 2) to dissect the arguments supporting this belief; and 3) to present the new framework of androgen adequacy versus inadequacy to explain the relationship of testosterone and prostate cancer. A MEDLINE review of the literature was performed. The belief that testosterone (T) drives prostate cancer (PCa) originated with Charles Huggins in 1941, led to a near-complete prohibition against T therapy (TTh) for 60 years, and persists today in regulatory warnings, guideline restrictions, and widespread clinical concerns. However, the evidence is now overwhelming that T does not drive PCa. Biopsy studies show PCa risk is unrelated to endogenous androgen concentrations. Large RCTs reveal identical PCa rates in men receiving TTh versus placebo. TTh in men with known PCa has not shown increased rates of recurrence or progression. While androgens are required for PCa growth, PCa growth also requires other chemicals, e.g., calcium. What is unique to androgens is it is the only required chemical that does not cause loss of life with severe deprivation. The key concept to understand the relationship of androgens and PCa is adequacy versus inadequacy. Adequate T concentrations for optimal PCa growth occur at a low concentration called the saturation point. Below this, cellular metabolism is compromised and cell death may occur depending on degree of deprivation. Testosterone does not drive prostate cancer. Androgen adequacy versus inadequacy provides a scientifically sound framework to understand the relationship of testosterone and prostate pathophysiology.
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (6) , 688-701
Testosterone Does Not Drive Prostate Cancer: Presenting the New Framework of Androgen Adequacy vs Inadequacy
1) To review the evidence whether "testosterone drives prostate cancer"; 2) to dissect the arguments supporting this belief; and 3) to present the new framework of androgen adequacy versus inadequacy to explain the relationship of testosterone and prostate cancer. A MEDLINE review of the literature was performed. The belief that testosterone (T) drives prostate cancer (PCa) originated with Charles Huggins in 1941, led to a near-complete prohibition against T therapy (TTh) for 60 years, and persists today in regulatory warnings, guideline restrictions, and widespread clinical concerns. However, the evidence is now overwhelming that T does not drive PCa. Biopsy studies show PCa risk is unrelated to endogenous androgen concentrations. Large RCTs reveal identical PCa rates in men receiving TTh versus placebo. TTh in men with known PCa has not shown increased rates of recurrence or progression. While androgens are required for PCa growth, PCa growth also requires other chemicals, e.g., calcium. What is unique to androgens is it is the only required chemical that does not cause loss of life with severe deprivation. The key concept to understand the relationship of androgens and PCa is adequacy versus inadequacy. Adequate T concentrations for optimal PCa growth occur at a low concentration called the saturation point. Below this, cellular metabolism is compromised and cell death may occur depending on degree of deprivation. Testosterone does not drive prostate cancer. Androgen adequacy versus inadequacy provides a scientifically sound framework to understand the relationship of testosterone and prostate pathophysiology.
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (2) , 438-450
Real-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study of Over 9,000 Men
Clift AK, et al. World J Mens Health. 2026 Jan;44:e6. https://doi.org/10.5534/wjmh.250245
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (2) , 438-450
Open AccessReal-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study of Over 9,000 Men
Clift AK, et al. World J Mens Health. 2026 Jan;44:e6. https://doi.org/10.5534/wjmh.250245
- 3 July 2025
- Published by Springer Nature
- p. 401-407
Testosterone Therapy and the Prostate
- Open Access
- 1 June 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (6) , 1759-1764
Testosterone threshold, assay and costs among laboratories for hypogonadism diagnosis
Background: The diagnosis of testosterone deficiency (hypogonadism) requires documentation of low testosterone concentration. Despite the thresholds for low testosterone established by various guidelines, non-expert physicians rely on reference ranges provided by laboratories. The objective of this study was to determine the consistency of laboratory-established reference ranges for total testosterone (TT) among Mexico City clinical laboratories. Methods: Information was requested from 202 laboratories in Mexico City in August 2024. The items of interest included the TT reference ranges, equipment, assays, and costs. Results: The responses were obtained from 134 laboratories. There were 27 different sets of reference ranges used in this study. The high TT threshold ranged from 400 to 1,719 ng/dL (variability: 487%), whereas the lower limit ranged from 84 to 470 ng/dL (variability: 426%). Five measurement methods were described, and the most frequently used was chemiluminescence 69 (51.11%), followed by electrochemiluminescence 25 (18.65%). The cost ranged from $9–160 USD, with a mean of $35 USD. Conclusions: The extreme variability in laboratory-established TT reference ranges represents a major challenge for the appropriate diagnosis and management of men with symptomatic testosterone deficiency. Although these results were obtained in Mexico City, there is good reason to believe that this problem exists globally.
- 1 June 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (6) , 1759-1764
Open AccessTestosterone threshold, assay and costs among laboratories for hypogonadism diagnosis
Background: The diagnosis of testosterone deficiency (hypogonadism) requires documentation of low testosterone concentration. Despite the thresholds for low testosterone established by various guidelines, non-expert physicians rely on reference ranges provided by laboratories. The objective of this study was to determine the consistency of laboratory-established reference ranges for total testosterone (TT) among Mexico City clinical laboratories. Methods: Information was requested from 202 laboratories in Mexico City in August 2024. The items of interest included the TT reference ranges, equipment, assays, and costs. Results: The responses were obtained from 134 laboratories. There were 27 different sets of reference ranges used in this study. The high TT threshold ranged from 400 to 1,719 ng/dL (variability: 487%), whereas the lower limit ranged from 84 to 470 ng/dL (variability: 426%). Five measurement methods were described, and the most frequently used was chemiluminescence 69 (51.11%), followed by electrochemiluminescence 25 (18.65%). The cost ranged from $9–160 USD, with a mean of $35 USD. Conclusions: The extreme variability in laboratory-established TT reference ranges represents a major challenge for the appropriate diagnosis and management of men with symptomatic testosterone deficiency. Although these results were obtained in Mexico City, there is good reason to believe that this problem exists globally.
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 661-662
Abraham Morgentaler, MD, FACS
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 661-662
Abraham Morgentaler, MD, FACS
- Open Access
- 8 January 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 80, 103061
O’ testosterone, where is thy sting? A Urologist's reflection on testosterone and prostate cancer
- 8 January 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 80, 103061
Open AccessO’ testosterone, where is thy sting? A Urologist's reflection on testosterone and prostate cancer
- 17 December 2024
- Published by Springer Nature
- p. 401-415
Testosterontherapie und Prostatakrebs